Informazioni generali
  • Categoria della malattia Lesione / ferita , Malattie del sistema nervoso (BASEC)
  • Fase dello studio N/A (ICTRP)
  • Stato di reclutamento reclutamento in corso (BASEC/ICTRP)
  • Luogo dello studio
    Losanna, Luzern
    (BASEC)
  • Responsabile dello studio Prof. Dr. Jocelyne Bloch neurorestore.studies@chuv.ch (BASEC)
  • Fonte dati BASEC: Importato da 06.05.2026 ICTRP: Importato da 02.05.2026
  • Ultimo aggiornamento 06.05.2026 14:11
HumRes67904 | SNCTP000006832 | BASEC2025-D0076 | NCT07234903

Spinal Cord Stimulation for Restoring Walking Function in People with Spinal Cord Injury

  • Categoria della malattia Lesione / ferita , Malattie del sistema nervoso (BASEC)
  • Fase dello studio N/A (ICTRP)
  • Stato di reclutamento reclutamento in corso (BASEC/ICTRP)
  • Luogo dello studio
    Losanna, Luzern
    (BASEC)
  • Responsabile dello studio Prof. Dr. Jocelyne Bloch neurorestore.studies@chuv.ch (BASEC)
  • Fonte dati BASEC: Importato da 06.05.2026 ICTRP: Importato da 02.05.2026
  • Ultimo aggiornamento 06.05.2026 14:11

Descrizione riassuntiva dello studio

In this study, we investigate how the intervention method ARC-IM therapy works and whether it is safe and effective in restoring some mobility functions. The ARC-IM therapy uses a medical device that is implanted in the body and sends electrical signals directly to the spinal cord to activate nerve pathways that have partially or completely lost their connection to the brain due to spinal cord injury. The medical device consists of a neurostimulator, a small device similar to a pacemaker. The electrical signals are sent to the lead, a plate made up of several small electrodes. These electrodes touch the outermost protective layer of the spinal cord, allowing the electrical signals to pass through and reach the nerves. In our study, participants are assigned to a group based on the time since their spinal cord injury. Both groups receive the same ARC-IM therapy. There are two groups in our study: Group 1 (subacute SCI group): includes individuals whose injury occurred less than 6 weeks prior to the start of the study; Group 2 (chronic SCI group): includes individuals whose injury occurred more than one year prior to the start of the study. Participation in this study lasts 4 years. The main study period includes an implantation surgery under general anesthesia, an 18-week configuration and treatment phase, and a less intensive 24-week follow-up phase, followed by a 3-year safety follow-up phase.

(BASEC)

Intervento studiato

The ARC-IM therapy uses a medical device (ARC-IM lumbar system) that is implanted in the body and sends electrical signals directly to the spinal cord (epidural electrical stimulation) to activate nerve pathways that have partially or completely lost their connection to the brain due to spinal cord injury.

(BASEC)

Malattie studiate

Subacute and Chronic Spinal Cord Injury

(BASEC)

Criteri di partecipazione
- Must be classified according to the ASIA Impairment Scale (AIS) into level A, B, C, or D. - Must have a spinal cord injury at the level of Th10 or higher according to ISNCSCI. - The injury must have occurred either less than 6 weeks before the start of the study (subacute spinal cord injury group) or more than 1 year before enrollment in the study (chronic spinal cord injury group). (BASEC)

Criteri di esclusione
- There must be no existing contraindications for mobility functions (e.g., unhealed fractures, central nervous system disorders, peripheral nerve disorders, etc.). - Must not have spinal cord injuries due to causes other than trauma (ischemic, tumor-related, autoimmune, etc.). - Must not have participated in another clinical study with drugs or medical devices in the 30 days prior to and during the current study. - No stem cells must have been injected into the spinal cord previously. - No active implanted devices should be present. (BASEC)

Luogo dello studio

Losanna, Luzern

(BASEC)

Switzerland (ICTRP)

Sponsor

École Polytechnique Fédérale de Lausanne (EPFL) Represented by Prof. Grégoire Courtine

(BASEC)

Contatto per ulteriori informazioni sullo studio

Persona di contatto in Svizzera

Prof. Dr. Jocelyne Bloch

+41 79 556 29 51

neurorestore.studies@chuv.ch

Centre Hospitalier Universitaire de Lausanne

(BASEC)

Informazioni generali

CHUVSPZ

+41 79 556 29 51

jocelyne.bloch@chuv.ch

(ICTRP)

Nome del comitato etico approvante (per studi multicentrici solo il comitato principale)

Commissione d'etica Vaud

(BASEC)

Data di approvazione del comitato etico

05.03.2026

(BASEC)


ID di studio ICTRP
NCT07234903 (ICTRP)

Titolo ufficiale (approvato dal comitato etico)
ARC-IM Therapy to support and promote recovery of ambulatory functions in people with subacute and chronic spinal cord injury (BASEC)

Titolo accademico
ARC-IM Therapy To Support and Promote Recovery of Ambulatory Functions in People With Subacute and Chronic Spinal Cord Injury (ICTRP)

Titolo pubblico
ARC-IM Therapy To Support and Promote Recovery of Ambulatory Functions in People With Subacute and Chronic Spinal Cord Injury (ICTRP)

Malattie studiate
Spinal Cord InjurySCISCI - Spinal Cord InjurySubacute Spinal Cord InjuryChronic Spinal Cord InjurySpinal Cord Injury (SCI) (ICTRP)

Intervento studiato
Device: ARC-IM Therapy (ICTRP)

Tipo di studio
Interventional (ICTRP)

Disegno dello studio
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). (ICTRP)

Criteri di inclusione/esclusione
Inclusion Criteria:

1. Must be at least 18 years old and no older than 65 years old at the time of
enrollment.

2. Must be graded A, B, C, or D in the ASIA Impairment Scale (AIS).

3. Must have a SCI level at T10 or higher as determined by ISNCSCI, with the region
extending 6 cm above the tip of the conus remaining anatomically intact as
determined by MRI.

4. Must have sustained their injury either less than 6 weeks prior to baseline (Group
"Subacute SCI"), or more than 1 year prior to enrollment (Group "Chronic SCI").

5. Must be suffering from a SCI due to trauma.

6. Must have a stable medical, physical and psychological condition as considered by
the investigators and the delegated specialists.

7. Must have residual upper limb function to use the arms for weight bearing support
(as determined by functional demonstration).

8. Must be able to understand and interact with the study team in German, French or
English.

9. Must agree to comply in good faith with all conditions of the study and to attend
all scheduled appointments.

10. Must provide Informed Consent as documented by signature prior to any study-related
procedures.

11. Must have an acceptable or highly effective method of contraception for women of
childbearing capacity.

Exclusion Criteria:

1. Must not be pregnant nor breastfeeding.

2. Must not have brain damage.

3. Must not have a history of epilepsy

4. Must not have participated in another clinical study using drugs or medical devices
within the 30 days preceding and during the present study.

5. Must not have previously been injected with stem cells in the spinal cord.

6. Must not have any diseases and conditions that would increase the morbidity and
mortality of SCI surgery.

7. Must not require ventilator support.

8. Must not have any existing contraindication to mobility functions (e.g., unhealed
bone fractures, central nervous system disorder, peripheral nerve disorder, etc.).

9. Must not suffer from SCI from other etiology than trauma (ischemic, tumoral,
autoimmune, etc.).

10. Must not have any anatomical limitations in the implantation area as judged by the
investigators (e.g., spinal stenosis, limiting protrusions, post-traumatic bone
damage at area of implantation).

11. Must not require the use of an intrathecal baclofen pump.

12. Must not have any active implanted devices.

13. Must not have any other conditions that would make the subject unable to participate
in testing in the judgment of the investigators (e.g., renal failure, hepatic
dysfunction, cardiovascular disease, etc.).

14. Must not be the investigator him/herself, his/her family members, employees or other
dependent persons. (ICTRP)

non disponibile

Endpoint primari e secondari
Occurrence of Serious Adverse Events and Adverse Events that are deemed related or possibly related to the study procedure or to ARC-IM Therapy, from implantation up to the end of the study. (ICTRP)

Spinal Cord Injury Functional Ambulation Inventory (SCI-FAI);American Spinal Injury Association (ASIA) International Standards for the Neurological Classification of Spinal Cord Injury (ISNCSCI);10-Meter Walk Test (10MWT);6-Minute Walk Test (6MWT);Timed Up and Go (TUG);Walking Index for Spinal Cord Injury version II (WISCI II);Gait Analysis;Goal Attainment Scale (GAS);Berg Balance Scale (BBS) (ICTRP)

Data di registrazione
non disponibile

Inclusione del primo partecipante
non disponibile

Sponsor secondari
non disponibile

Contatti aggiuntivi
Jocelyne Bloch, Prof. Dr. MDBjrn Zrner, PD Dr. med. Dr. sc. nat.Jocelyne Bloch, Prof. Dr. MD, jocelyne.bloch@chuv.ch, +41 79 556 29 51, CHUVSPZ (ICTRP)

ID secondari
EIGER (ICTRP)

Risultati-Dati individuali dei partecipanti
non disponibile

Ulteriori informazioni sullo studio
https://clinicaltrials.gov/study/NCT07234903 (ICTRP)

Risultati dello studio

Riepilogo dei risultati

non disponibile

Link ai risultati nel registro primario

non disponibile